Mar. 12, 2015News & Opinions
Bayer aims to achieve strong sales and earnings growth for its life science businesses in the coming years, CEO Marijn Dekkers said at the "Meet Management" investor conference in Berlin, Germany.
Dec. 17, 2014News & Opinions
Bayer's Eylea (VEGF Trap-Eye) is not more effective than its competitor Lucentis to treat patients with diabetic macular edema, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found.
Sep. 16, 2014News & Opinions
Roche's cancer drug Avastin as a cheaper treatment for wet age-related macular degeneration (wAMD), a leading cause of blindness in the elderly, does not appear to increase deaths or serious side effects, an independent study has concluded.
May. 29, 2014News & Opinions
As expected, Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox manufacturer Allergan on May 28. Its new offer values the US firm at $49.44 billion.
Jan. 06, 2014News & Opinions
Bayer HealthCare has hit a stumbling block in the sales campaign for its new drug Eylea (aflibercept), or VEGF Trap-Eye, recommended for treatment of age-related wet macula degeneration (AMD). The German Institute for Quality and ...
Jul. 30, 2013News & Opinions
Expectations that Bayer will embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve.
May. 07, 2013News & Opinions
Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of ...
Feb. 11, 2013News & Opinions
Regeneron Pharmaceuticals said its longtime drug-development partner Sanofi aims to boost its stake in the U.S. biotechnology company through open market purchases of its stock.
Dec. 06, 2012News & Opinions
Success Factors - With numerous new products, the Bayer Group aims to help improve people's lives while exploiting billions in potential sales. "Innovation is the only way to address the global challenges that exist at the beginning of the ...
The latest information directly via newsletter.